drugset
drugset / Trial / NCT00096447

Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT00096447 ↗

Phase 2 Completed 31 enrolled National Cancer Institute (NCI) Gynecologic Oncology Group · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well lapatinib works in treating patients with recurrent or persistent endometrial cancer. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth

Timeline

Start
2004-11
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Lapatinib Small molecule — Oral

Indications

endometrial carcinoma